SequelSEC

Apimeds Pharmaceuticals US, Inc. APUS

Pharmaceutical Preparations · CIK 0001894525 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$11.91M
Fiscal year ended 2025-12-31
Free cash flow
-$8.98M
Fiscal year ended 2025-12-31

Apimeds Pharmaceuticals US, Inc. (APUS) reported net income of -$6.00M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Apimeds Pharmaceuticals US, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Apimeds Pharmaceuticals US, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$11.91M-$1.28M-$747.44K
Net income-$6.00M-$1.39M-$777.69K
Research & development$1.63MUnavailable$98.54K
Weighted-average diluted sharesshares 10.88Mshares 7.90MUnavailable
Pretax incomeUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailable
Diluted EPS$-0.55$-0.18$-0.17
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$10.28M$1.28M$648.89K
Selling & marketingUnavailableUnavailableUnavailable

Balance

Apimeds Pharmaceuticals US, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$1.64M$3.46K$410.48K
Total assets$164.18M$13.06K$422.08K
Current assets$13.98M$13.06K$422.08K
Total liabilities$10.84M$1.37M$390.21K
Current liabilities$10.71M$1.02M$123.32K
Total equity incl. NCI$153.35M-$1.36M$31.87K
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailable

Cash flow

Apimeds Pharmaceuticals US, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$8.93M-$733.53K-$627.79K
Capital expenditures$57.33KUnavailableUnavailable
Investing cash flow-$10.06MUnavailableUnavailable
Financing cash flow$20.62M$326.50K$1.03M
Net change in cashUnavailableUnavailableUnavailable
Stock-based compensation$1.57MUnavailable$69.99K
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Apimeds Pharmaceuticals US, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$8.98MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio1.31x0.01x3.42x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open APUS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-26View SEC filing
10-K · Filed 2026-05-04View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-05-20View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.